Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Unicycive Therapeutics is a clinical-stage biotech focused on developing innovative kidney disease therapies. Its pipeline includes Oxylanthanum Carbonate, a phosphate binder for hyperphosphatemia, and UNI-494, a potential treatment for acute kidney injury and delayed graft function. The company licenses assets, advances clinical trials, and aims to improve patient adherence and outcomes in renal care markets globally.
This description was generated via AI from an annual report. Updated about 1 year ago.